• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A deeper quiet: Tofacitinib and the potential of endo-histologic remission.

作者信息

Hassan Syed Adeel, Bishu Shrinivas

机构信息

Division of Gastroenterology, University of Michigan, Ann Arbor, USA.

出版信息

Indian J Gastroenterol. 2025 Jul 14. doi: 10.1007/s12664-025-01792-6.

DOI:10.1007/s12664-025-01792-6
PMID:40658341
Abstract
摘要

相似文献

1
A deeper quiet: Tofacitinib and the potential of endo-histologic remission.更深层次的缓解：托法替布与组织学内缓解的潜力。
Indian J Gastroenterol. 2025 Jul 14. doi: 10.1007/s12664-025-01792-6.
2
Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib.对托法替布有反应的溃疡性结肠炎患者的内镜组织学结果
Indian J Gastroenterol. 2025 Jun 24. doi: 10.1007/s12664-025-01779-3.
3
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.生物制剂或托法替布用于生物制剂治疗类风湿关节炎失败的患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.
4
Prospective observational study of tofacitinib in ulcerative colitis - analysis of clinical data, fatigue and health-related quality of life during the induction phase.托法替布治疗溃疡性结肠炎的前瞻性观察研究——诱导期临床数据、疲劳及健康相关生活质量分析
Therap Adv Gastroenterol. 2025 Jun 16;18:17562848251343427. doi: 10.1177/17562848251343427. eCollection 2025.
5
Endo-Histo foundational fusion model: a novel artificial intelligence for assessing histologic remission and response to therapy in ulcerative colitis clinical trial.内镜-组织学基础融合模型：一种用于评估溃疡性结肠炎临床试验中组织学缓解及治疗反应的新型人工智能技术。
J Crohns Colitis. 2025 Jul 3;19(7). doi: 10.1093/ecco-jcc/jjaf108.
6
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC).托法替布和维多珠单抗作为抗 TNF 药物治疗后溃疡性结肠炎二线治疗的真实疗效和安全性：一项多中心队列 IGIBD 研究（VE2TO-UC）
Dig Liver Dis. 2025 May 6. doi: 10.1016/j.dld.2025.04.025.
7
Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial.接受托法替布治疗的幼年特发性关节炎患者的临床非活动性疾病和缓解：一项III期试验的事后分析
J Rheumatol. 2025 Jul 1. doi: 10.3899/jrheum.2024-0536.
8
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).生物制剂或托法替布单药治疗传统抗风湿药物（DMARD）治疗失败的类风湿关节炎患者：一项Cochrane系统评价和网状Meta分析（NMA）
Cochrane Database Syst Rev. 2016 Nov 17;11(11):CD012437. doi: 10.1002/14651858.CD012437.
9
Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison.初治溃疡性结肠炎患者中托法替布与维多珠单抗的比较：一项真实世界倾向加权比较
J Crohns Colitis. 2025 Jul 3;19(7). doi: 10.1093/ecco-jcc/jjae188.
10
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.

本文引用的文献

1
Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice.托法替布在溃疡性结肠炎中的应用：日常临床实践专家共识
Indian J Gastroenterol. 2024 Feb;43(1):22-35. doi: 10.1007/s12664-023-01507-9. Epub 2024 Feb 12.
2
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.托法替布治疗生物制剂治疗后住院的急性重度溃疡性结肠炎患者：一项回顾性病例对照研究。
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2112-2120.e1. doi: 10.1016/j.cgh.2021.05.038. Epub 2021 May 25.
3
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
STRIDE-II：炎症性肠病（STRIDE）国际研究组织（IOIBD）治疗靶点选择更新：确定炎症性肠病靶向治疗策略的治疗目标。
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
4
Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.内镜和组织学缓解对溃疡性结肠炎患者获益的增量分析：系统评价和荟萃分析。
Gastroenterology. 2020 Oct;159(4):1262-1275.e7. doi: 10.1053/j.gastro.2020.06.043. Epub 2020 Jun 22.
5
Transcriptional Signatures That Define Ulcerative Colitis in Remission.定义缓解期溃疡性结肠炎的转录特征。
Inflamm Bowel Dis. 2021 Jan 1;27(1):94-105. doi: 10.1093/ibd/izaa075.
6
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.JAK-STAT 通路靶向治疗炎症性肠病。
Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):323-337. doi: 10.1038/s41575-020-0273-0. Epub 2020 Mar 19.
7
Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.4 例急性重度溃疡性结肠炎患者应用高强度托法替布诱导治疗的疗效。
Clin Gastroenterol Hepatol. 2019 Apr;17(5):988-990.e1. doi: 10.1016/j.cgh.2018.11.022. Epub 2018 Nov 17.
8
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.宿主-微生物相互作用塑造了炎症性肠病的遗传结构。
Nature. 2012 Nov 1;491(7422):119-24. doi: 10.1038/nature11582.